Management of cancer genomic board and preparation of genomic report

Kohei Nakamura, Hiroshi Nishihara

Research output: Contribution to journalArticlepeer-review

Abstract

The accumulation of gene alteration is the major pathogenicity of any types of cancer. The concept of precision cancer medicine is therefore the individualized treatment based on the driver gene alteration in each case. The cancer gene profiling (CGP) test, so called gene panel test, will be the major clinical examination to identify the driver gene alteration usually using the FFPE tissue from the surgically resected pathological archives, and government insurance system will cover the examination fee for limited number of cancer patients since 2019 in Japan. Although genetic profiling of tumors is a potentially powerful tool to predict drug sensitivity and resistance, its routine use has been limited because physicians are often unfamiliar with interpretation and incorporation of the information into practice. We established a molecular tumor board (MTB) and clinical tumor board (CTB) system to interpret individual patients' tumor genetic profiles and provide treatment recommendations upon the molecular report.

Original languageEnglish
Pages (from-to)1141-1148
Number of pages8
JournalJapanese Journal of Cancer and Chemotherapy
Volume47
Issue number8
Publication statusPublished - 2020 Aug

Keywords

  • Cancer gene profiling test
  • Cancer genomic board
  • Clinical tumor board (CTB)
  • Molecular tumor board (MTB)
  • Precision medicine

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Management of cancer genomic board and preparation of genomic report'. Together they form a unique fingerprint.

Cite this